Universal infant vaccination with timely birth dose and peripartum
antiviral prophylaxis in mothers with a high level of HBV DNA can
effectively prevent mother-to-child transmission, but these are currently
underutilized, recent study revealed.
antiviral prophylaxis in mothers with a high level of HBV DNA can
effectively prevent mother-to-child transmission, but these are currently
underutilized, recent study revealed.
Prompt action is needed to remove the barriers that disrupt the current
HBV care cascade and to close the gaps in HBV prevention, screening,
diagnosis, linkage to care, antiviral treatment and liver cancer
surveillance.
Globally, approximately 296 million people are currently living with
hepatitis B virus (HBV), and the burden disproportionately affects
sub-Saharan Africa and East Asia.
Cirrhosis and liver cancer account for most HBV-related deaths, with
acute flares and reactivation, extrahepatic complications, and social
stigma further contributing to the burden of HBV. Underdiagnosis and low
treatment rates of chronic HBV infection are serious even in high-income
countries
